about
Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy CooperatSuccessful outcome after combined chemotherapeutic and surgical management in a case of esophageal cancer with breast and brain relapse.Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.Atypical primary pulmonary meningioma: a report of a case suspected of being a lung metastasis.Bronchial mucoepidermoid carcinoma: A case report.Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.Oligometastatic non-small cell lung cancer: a multidisciplinary approach in the positron emission tomographic scan era.Target-Treatment and Patients' Selection: Can We Still Neglect the Timing of Tissue Collection?Deciduoid mesothelioma of the thorax: A comprehensive review of the scientific literaturePhase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylateIntra-patient alternated dose escalation of paclitaxel and gemcitabine versus paclitaxel followed by fixed dose rate infusion of gemcitabine in fit elderly non-small cell lung cancer patients. A Southern Italy Cooperative Oncology Group randomised pEfficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experienceBlood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with NivolumabActivity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations
P50
Q33373124-4FFAFA3B-1846-4973-8504-24A9773CC9A4Q33869588-73A79E99-E327-4000-9F77-35DA0763D2EDQ37340755-FC5DBDA9-8CC7-4F1E-ACDC-B3EE37C9DF82Q37677844-871B1581-AABE-4967-A29F-1DF1FA22EC7DQ40070719-08BE977B-8AB4-4C57-A65B-710C21A62A09Q47632061-B645E673-B9A1-499D-8234-8B2266C67280Q48330307-72A29410-F536-4B8C-9D8B-DFE47B1021FDQ57580845-34A5BF5D-4967-4CC0-BEE7-644F43FBA7C3Q57781438-8B0474C9-2B42-40E8-B019-376F8E4D528CQ61794203-5BC68596-C3E3-4A0E-ACB6-DA1668BF054CQ79770561-9DD1C8A5-ADC6-4930-9FAA-A5FF0D986192Q84189190-CC1E2C81-003A-442F-BDA7-D99846BE9162Q89281994-4A8B1E6D-0B55-4D24-9996-773D1CE83C44Q90621386-52B4DC7A-632F-4D7C-BD2A-120539A63695
P50
description
researcher ORCID ID = 0000-0002-2174-9462
@en
wetenschapper
@nl
name
Carlo Putzu
@ast
Carlo Putzu
@en
Carlo Putzu
@es
Carlo Putzu
@nl
type
label
Carlo Putzu
@ast
Carlo Putzu
@en
Carlo Putzu
@es
Carlo Putzu
@nl
prefLabel
Carlo Putzu
@ast
Carlo Putzu
@en
Carlo Putzu
@es
Carlo Putzu
@nl
P1153
14827158400
P31
P496
0000-0002-2174-9462